StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Cash and Short-Term Investments for the year ending July 31, 2024: USD 56.10 M

StemRIM Cash and Short-Term Investments is USD 56.10 M for the year ending July 31, 2024, a -21.87% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

StemRIM Cash and Short-Term Investments for the year ending July 31, 2023 was USD 71.80 M, a 7.75% change year over year.
StemRIM Cash and Short-Term Investments for the year ending July 31, 2022 was USD 66.64 M, a -28.13% change year over year.
StemRIM Cash and Short-Term Investments for the year ending July 31, 2021 was USD 92.72 M, a -7.97% change year over year.
StemRIM Cash and Short-Term Investments for the year ending July 31, 2020 was USD 100.75 M, a 339.16% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years